Re: Farmas USA
XOMA última hora
Por lo visto van iniciar una demanda colectiva por alentar y decir que los resultados del medicamento serian positivos y ocurrió lo contrario dejando enganchados a muchos inversores.
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Xoma Corporation and a Lead Plaintiff Deadline of September 22, 2015 - XOMA
NEW YORK, Sep 11, 2015 (GLOBE NEWSWIRE via COMTEX) --
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Xoma Corporation (NASDAQ:XOMA) securities between November 6, 2014 and July 21, 2015.
Click here to learn about the case: http://docs.wongesq.com/XOMA-Info-Request-Form-863. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements that Xoma Corporation's EYEGUARD-B clinical trial would succeed and/or surpass expectations across the study's primary endpoint. On July 22, 2015, defendants revealed that the Phase 3 EYEGUARD-B study had failed. On this news, the price of Xoma stock declined by $3.48 per share, or over 79%, on extremely heavy trading volume.
If you suffered a loss in Xoma you have until September 22, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/XOMA-Info-Request-Form-863.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
